EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Candidate anti-tuberculosis medicines and regimens under clinical evaluation

Michael Hoelscher, David Barros-Aguirre, Masoud Dara, Norbert Heinrich, Eugene Sun, Christoph Lange, Simon Tiberi, Charles Wells

Clinical Microbiology and Infection · 2024

DOI: 10.1016/j.cmi.2024.06.016 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Microbiology and Infection, 2024. Verfasst von Michael Hoelscher und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany; German Centre for Infection Research, Partner Site …. Hauptthemen laut MEDLINE: Antitubercular Agents, Mycobacterium tuberculosis, Tuberculosis. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bundesministerium für Forschung, Technologie und Raumfahrt, Deutsches Zentrum für Infektionsforschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Tuberculosis (TB) is the leading cause of mortality by an infectious disease worldwide. Despite national and international efforts, the world is not on track to end TB by 2030. Antibiotic treatment of TB is longer than for most infectious diseases and is complicated by frequent adverse events. To counter emerging Mycobacterium tuberculosis drug resistance and provide effective, safe drug treatments of shorter duration, novel anti-TB medicines, and treatment regimens are needed. Through a joint global effort, more candidate medicines are in the clinical phases of drug development than ever before. OBJECTIVES: To review anti-TB medicines and treatment regimens under clinical evaluation for the future treatment of drug-susceptible and drug-resistant TB. SOURCES: Pre-clinical and clinical studies on novel anti-TB drugs. CONTENT: Description of novel protein synthesis inhibitors (oxazolidinones and oxaboroles), respiratory chain inhibitors (diarylquinolines and cytochrome bc1 complex inhibitor), cell wall inhibitors (decaprenylphosphoryl-β-d-ribose 2'-epimerase, inhibitors, thioamides, and carbapenems), and cholesterol metabolism inhibitor currently evaluated in clinical trials and novel clinical trial platforms for the evaluation of treatment regimens, rather than single entities. IMPLICATIONS: A large number of potential anti-TB candidate medicines and innovations in clinical trial design for the evaluation of regimens, rather than single medicines, provide hope for improvements in the treatment of TB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsMycobacterium tuberculosisTuberculosisHumansTuberculosis, Multidrug-ResistantClinical Trials as TopicAdaptive Clinical Trials as Topic

Stichwörter der Autor:innen

Clinical trialsDrug classesPlatform trialsTBUNITE4TB

Substanzen

Antitubercular Agents

Autor:innen und Institutionen

  • Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany; German Centre for Infection Research, Partner Site Munich, Munich, Germany; Fraunhofer Institute ITMP, Immunology, Infect…
  • GSK, Tres Cantos, Spain.
  • Otsuka Novel Products GmbH, Munich, Germany.
  • TB Alliance, New York, NY, United States.
  • Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany; Respiratory Medicine and Int…
  • GSK, Brentford, United Kingdom; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

Förderung

  • Bundesministerium für Forschung, Technologie und Raumfahrt
  • Deutsches Zentrum für Infektionsforschung

Zitieren

APA

Hoelscher, M., Barros-Aguirre, D., Dara, M., Heinrich, N., Sun, E., Lange, C., Tiberi, S., & Wells, C. (2024). Candidate anti-tuberculosis medicines and regimens under clinical evaluation. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2024.06.016

Vancouver

Hoelscher M, Barros-Aguirre D, Dara M, Heinrich N, Sun E, Lange C, et al. Candidate anti-tuberculosis medicines and regimens under clinical evaluation. Clinical Microbiology and Infection. 2024. doi:10.1016/j.cmi.2024.06.016

BibTeX
@article{Hoelscher2024,
  author = {Hoelscher, Michael and Barros-Aguirre, David and Dara, Masoud and Heinrich, Norbert and Sun, Eugene and Lange, Christoph and Tiberi, Simon and Wells, Charles},
  title = {Candidate anti-tuberculosis medicines and regimens under clinical evaluation},
  journal = {Clinical Microbiology and Infection},
  year = {2024},
  doi = {10.1016/j.cmi.2024.06.016}
}
Kostenlos starten →